Patients with type 2 diabetes can achieve cardiovascular protection from use of SGLT2 inhibitors

All type 2 diabetes patient subgroups are likely to achieve cardiovascular protection from the use of SGLT2 inhibitors, according to a large multi-study review published in the Journal of the American Heart Association.